Cartesian Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cartesian Therapeutics (RNAC).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$36Upside to Avg. PT+469.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
Sep 29, 2026	Needham	Gil Blum	Maintained	Buy	$40
Aug 18, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
Jun 10, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
Jun 9, 2026	Needham	Gil Blum	Maintained	Buy	$40
Jun 9, 2026	BTIG	Julian Harrison	Maintained	Buy	$44
May 27, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
May 26, 2026	Needham	Gil Blum	PT Cut	Buy	$42→$40
May 12, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$30→$25
May 1, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
Mar 10, 2026	Wedbush	Martin Fan	Maintained	Outperform	$38
Mar 9, 2026	Cantor Fitzgerald	Kristen Kluska	Upgrade	Neutral→Overweight	$16
Mar 9, 2026	Needham	Gil Blum	Maintained	Buy	$42
Jan 9, 2026	Needham	Gil Blum	PT Raise	Buy	$40→$42
Nov 19, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$40→$30
Nov 14, 2025	BTIG	Julian Harrison	PT Raise	Buy	$42→$44
Jul 9, 2025	Wedbush	Martin Fan	Initiate	Outperform	$38
May 8, 2025	Needham	Gil Blum	PT Cut	Buy	$41→$40
Apr 9, 2025	Needham	Gil Blum	Maintained	Buy	$41
Apr 9, 2025	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $44 price target.

Benzinga Newsdesk

Cartesian Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Cartesian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

People Also Watch

People Also Watch

Cartesian Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Cartesian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRONeedham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PROWedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PROWedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRONeedham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PROBTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

PRO
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

PRO
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target